ArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 7% - Time to Buy?

ArriVent BioPharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • ArriVent BioPharma shares rose 7% to about $11.66 in mid-day trading, although volume was 79% below its average.
  • Analysts’ consensus is “Moderate Buy,” with an average price target of $24.67; some firms recently cut targets, and ratings include one Hold and one Sell alongside nine Buys.
  • The company reported a quarterly loss of $0.81 per share, better than the $1.05 loss analysts expected, and revenue of $5 million versus a $0.8 million consensus estimate.
  • Interested in ArriVent BioPharma? Here are five stocks we like better.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report)'s stock price rose 7% during mid-day trading on Thursday. The company traded as high as $11.61 and last traded at $11.6630. Approximately 161,376 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 753,010 shares. The stock had previously closed at $10.90.

Analysts Set New Price Targets

Several research firms have recently commented on AVBP. Oppenheimer reissued an "outperform" rating and issued a $25.00 price target on shares of ArriVent BioPharma in a research report on Monday, October 26th. BTIG Research reaffirmed a "buy" rating and set a $29.00 price objective on shares of ArriVent BioPharma in a research report on Friday, October 16th. Guggenheim cut their target price on ArriVent BioPharma from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of ArriVent BioPharma in a report on Thursday, October 15th. Finally, JonesTrading reduced their target price on shares of ArriVent BioPharma from $45.00 to $22.00 and set a "buy" rating for the company in a report on Wednesday, October 7th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $24.67.

Check Out Our Latest Report on ArriVent BioPharma

ArriVent BioPharma Price Performance

The company's fifty day simple moving average is $20.20 and its 200-day simple moving average is $26.23. The firm has a market capitalization of $601.80 million, a PE ratio of -3.23 and a beta of 1.66.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $5.00 million for the quarter, compared to analysts' expectations of $0.80 million. As a group, equities research analysts anticipate that ArriVent BioPharma, Inc. will post -3.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ArriVent BioPharma

Institutional investors have recently added to or reduced their stakes in the business. Montanova Capital LLC raised its position in shares of ArriVent BioPharma by 2.6% in the 2nd quarter. Montanova Capital LLC now owns 4,515,531 shares of the company's stock valued at $156,870,000 after purchasing an additional 114,448 shares during the last quarter. Hhlr Advisors LTD. acquired a new position in ArriVent BioPharma during the 2nd quarter valued at approximately $136,498,000. BlackRock Inc. acquired a new position in ArriVent BioPharma during the 2nd quarter valued at approximately $112,919,000. General Catalyst Group Management LLC purchased a new position in shares of ArriVent BioPharma in the second quarter worth $51,929,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of ArriVent BioPharma by 29.7% in the third quarter. Goldman Sachs Group Inc. now owns 1,107,094 shares of the company's stock worth $33,523,000 after buying an additional 253,371 shares during the last quarter. Institutional investors and hedge funds own 9.48% of the company's stock.

About ArriVent BioPharma

(Get Free Report)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ArriVent BioPharma Right Now?

Before you consider ArriVent BioPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.

While ArriVent BioPharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines